Results 51 to 60 of about 2,653,331 (305)

HCV's days are numbered: Next-generation direct-acting antivirals and host-targeting agents

open access: yes, 2012
Chronic hepatitis C affects approximately 170 million people worldwide and is one of the leading causes of liver-related morbidity and mortality. Until 2011, the only therapeutic option was combination therapy of pegylated interferon and ribavirin, with ...
Serrano, Beatriz Calle   +1 more
core   +1 more source

Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer

open access: yesMolecular Oncology, EarlyView.
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim   +7 more
wiley   +1 more source

Hybrid immunity from bivalent vaccination and prior infection enhances humoral and innate protection against Omicron XBB.1.16 and EG.5.1.1 variants in Japan

open access: yesFrontiers in Immunology
IntroductionEmerging Omicron sublineages XBB.1.16 and EG.5.1.1 have caused breakthrough infections, challenging vaccine efficacy. Hybrid immunity—vaccination plus prior SARS-CoV-2 infection—augments neutralizing activity.
Kouki Matsuda   +14 more
doaj   +1 more source

Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: A scoping review

open access: yesAntiviral Therapy, 2023
Background:  Biktarvy is approved for use in HIV-1 infection in both treatment-naïve and treatment-experienced individuals, after a series of successful phase III trials.
Ellen Peters, and Collins Iwuji
doaj   +1 more source

From energy provision to protein synthesis: Tunnelling nanotubes as mediators of intercellular metabolic cooperation in cancer

open access: yesFEBS Open Bio, EarlyView.
The cytoskeleton‐mediated transport of mitochondria via tunnelling nanotubes restores respiration, increases ATP production, rescues cells from apoptosis, activates the AKT/mTOR signalling pathway, promotes cell migration and invasiveness, contributes to cancer progression and treatment resistance.
Stanislava Martínková, Jan Trnka
wiley   +1 more source

Pharmacokinetic interaction between raltegravir and rifampicin in an infant with HIV exposed to active TB: a case report

open access: yesAntiviral Therapy, 2022
We report a case of an infant with HIV receiving raltegravir granules for oral suspension and rifampicin-based TB prophylaxis. Raltegravir trough levels remained subtherapeutic and viral load increased during concurrent rifampicin therapy despite using ...
Marlotte AA van der Veer   +6 more
doaj   +1 more source

Antiviral

open access: yes, 2020
Antiviral in TXT ...
CHARLI DEEPAK ARULANANDAM (6542618)
core   +1 more source

Antiviral potential of cathelicidins [PDF]

open access: yes, 2014
The global burden of morbidity and mortality arising from viral infections is high; however, the development of effective therapeutics has been slow.
Davidson, Donald J   +4 more
core   +1 more source

Importin 7 mediates the nuclear import of HIV‐1 integrase via a specific interacting interface

open access: yesFEBS Open Bio, EarlyView.
HIV‐1 integrase enables viral DNA integration into the host genome. By binding to the core domain of the host protein Importin 7 via its C‐terminal domain, the integrase is transported across the nuclear membrane into the nucleus, where integration of the viral genome into host DNA takes place. This translocation is a critical step for subsequent viral
Juana Bana   +5 more
wiley   +1 more source

Antiviral Res.

open access: yes, 2014
Recombinant human interferon-omega (rhIFN-omega) exhibits a potent antiviral activity. Because of poor pharmacokinetics (PK) of rhIEN-omega, frequent dosing of rhIFN-omega is necessitated to achieve the sustained antiviral efficacy.
Fang, Ting   +9 more
core   +1 more source

Home - About - Disclaimer - Privacy